Cargando…
Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Thoracic Society
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10263136/ https://www.ncbi.nlm.nih.gov/pubmed/36996347 http://dx.doi.org/10.1164/rccm.202211-2128LE |
| _version_ | 1785058179539795968 |
|---|---|
| author | Birring, Surinder S. Dicpinigaitis, Peter V. Smith, Jaclyn A. Morice, Alyn H. McGarvey, Lorcan P. Pavord, Ian D. Nguyen, Allison Martin Schelfhout, Jonathan Li, Qing Iskold, Beata Green, Stuart A. Philip, George Muccino, David R. La Rosa, Carmen |
| author_facet | Birring, Surinder S. Dicpinigaitis, Peter V. Smith, Jaclyn A. Morice, Alyn H. McGarvey, Lorcan P. Pavord, Ian D. Nguyen, Allison Martin Schelfhout, Jonathan Li, Qing Iskold, Beata Green, Stuart A. Philip, George Muccino, David R. La Rosa, Carmen |
| author_sort | Birring, Surinder S. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10263136 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | American Thoracic Society |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-102631362023-06-15 Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks Birring, Surinder S. Dicpinigaitis, Peter V. Smith, Jaclyn A. Morice, Alyn H. McGarvey, Lorcan P. Pavord, Ian D. Nguyen, Allison Martin Schelfhout, Jonathan Li, Qing Iskold, Beata Green, Stuart A. Philip, George Muccino, David R. La Rosa, Carmen Am J Respir Crit Care Med Correspondence American Thoracic Society 2023-03-30 /pmc/articles/PMC10263136/ /pubmed/36996347 http://dx.doi.org/10.1164/rccm.202211-2128LE Text en Copyright © 2023 by the American Thoracic Society https://creativecommons.org/licenses/by-nc-nd/4.0/This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . For commercial usage and reprints, please e-mail Diane Gern (dgern@thoracic.org). |
| spellingShingle | Correspondence Birring, Surinder S. Dicpinigaitis, Peter V. Smith, Jaclyn A. Morice, Alyn H. McGarvey, Lorcan P. Pavord, Ian D. Nguyen, Allison Martin Schelfhout, Jonathan Li, Qing Iskold, Beata Green, Stuart A. Philip, George Muccino, David R. La Rosa, Carmen Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks |
| title | Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks |
| title_full | Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks |
| title_fullStr | Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks |
| title_full_unstemmed | Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks |
| title_short | Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks |
| title_sort | efficacy and safety of gefapixant for refractory or unexplained chronic cough over 52 weeks |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10263136/ https://www.ncbi.nlm.nih.gov/pubmed/36996347 http://dx.doi.org/10.1164/rccm.202211-2128LE |
| work_keys_str_mv | AT birringsurinders efficacyandsafetyofgefapixantforrefractoryorunexplainedchroniccoughover52weeks AT dicpinigaitispeterv efficacyandsafetyofgefapixantforrefractoryorunexplainedchroniccoughover52weeks AT smithjaclyna efficacyandsafetyofgefapixantforrefractoryorunexplainedchroniccoughover52weeks AT moricealynh efficacyandsafetyofgefapixantforrefractoryorunexplainedchroniccoughover52weeks AT mcgarveylorcanp efficacyandsafetyofgefapixantforrefractoryorunexplainedchroniccoughover52weeks AT pavordiand efficacyandsafetyofgefapixantforrefractoryorunexplainedchroniccoughover52weeks AT nguyenallisonmartin efficacyandsafetyofgefapixantforrefractoryorunexplainedchroniccoughover52weeks AT schelfhoutjonathan efficacyandsafetyofgefapixantforrefractoryorunexplainedchroniccoughover52weeks AT liqing efficacyandsafetyofgefapixantforrefractoryorunexplainedchroniccoughover52weeks AT iskoldbeata efficacyandsafetyofgefapixantforrefractoryorunexplainedchroniccoughover52weeks AT greenstuarta efficacyandsafetyofgefapixantforrefractoryorunexplainedchroniccoughover52weeks AT philipgeorge efficacyandsafetyofgefapixantforrefractoryorunexplainedchroniccoughover52weeks AT muccinodavidr efficacyandsafetyofgefapixantforrefractoryorunexplainedchroniccoughover52weeks AT larosacarmen efficacyandsafetyofgefapixantforrefractoryorunexplainedchroniccoughover52weeks |